Suppliers and packagers for generic pharmaceutical drug: DALFAMPRIDINE

DALFAMPRIDINE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Merz	AMPYRA	dalfampridine	TABLET, EXTENDED RELEASE;ORAL	022250	NDA	Merz Pharmaceuticals, LLC	0259-5010-60	60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0259-5010-60)	2010-03-01
Merz	AMPYRA	dalfampridine	TABLET, EXTENDED RELEASE;ORAL	022250	NDA	Merz Pharmaceuticals, LLC	10144-427-60	60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (10144-427-60)	2010-03-01
Accord Hlthcare	DALFAMPRIDINE	dalfampridine	TABLET, EXTENDED RELEASE;ORAL	206863	ANDA	Accord Healthcare Inc.	16729-292-12	60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (16729-292-12)	2018-09-18

Dalfampridine Drug Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the suppliers and manufacturing landscape for dalfampridine, a potassium channel blocker approved for improving walking in adults with multiple sclerosis. The analysis focuses on active pharmaceutical ingredient (API) manufacturers and key suppliers of starting materials and intermediates, assessing their capacity, regulatory standing, and potential impact on drug availability and cost.

What is Dalfampridine and Its Therapeutic Use?

Dalfampridine is an oral medication indicated to improve walking in adult patients with multiple sclerosis (MS). It functions by blocking voltage-gated potassium channels in demyelinated axons, which can enhance conduction in these compromised nerve fibers. This mechanism aims to restore neurological function, specifically improving motor coordination and ambulation. The drug is available under brand names such as Ampyra (U.S.) and Fampyra (Europe). Its efficacy is established in clinical trials demonstrating statistically significant improvements in walking speed.

Who Manufactures Dalfampridine API?

The manufacturing of the dalfampridine Active Pharmaceutical Ingredient (API) is primarily concentrated among a limited number of specialized chemical manufacturers. These entities possess the expertise and regulatory compliance to produce API meeting stringent pharmaceutical quality standards.

• Key API Manufacturers:
  • Catalent Pharma Solutions: A prominent contract development and manufacturing organization (CDMO) with a significant presence in API production. Catalent has a history of manufacturing dalfampridine API. Their facilities operate under current Good Manufacturing Practices (cGMP).
  • Hovione: A global API manufacturer with a strong track record in complex chemical synthesis. Hovione is known to supply dalfampridine API, adhering to strict regulatory requirements for pharmaceutical production.
  • Major Generic API Suppliers: Several large-scale generic API manufacturers, particularly in India and China, are also involved in the production of dalfampridine API. These suppliers are crucial for the broader market access and cost management of the drug. Specific company names often operate under confidentiality agreements with drug product manufacturers, but major players in this space include companies like Divi's Laboratories and Sun Pharmaceutical Industries due to their extensive API portfolios and cGMP compliance.

The presence of multiple API suppliers mitigates supply chain risk. However, the reliance on a few key players, particularly for specialized synthesis steps, can still present vulnerabilities. Regulatory scrutiny on API manufacturing sites, including inspections by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), directly impacts the security of the dalfampridine supply.

What Are the Key Starting Materials and Intermediates for Dalfampridine Synthesis?

The synthesis of dalfampridine involves a multi-step chemical process. Identifying the critical starting materials and intermediates provides insight into potential supply chain bottlenecks and cost drivers. The primary chemical structure of dalfampridine is 4-aminopyridine.

• Primary Starting Material:

  • Pyridine: This is the fundamental heterocyclic aromatic organic compound from which dalfampridine is ultimately derived. The availability and purity of pyridine are foundational to the entire synthesis chain. Suppliers of pyridine include major chemical producers globally.

• Key Intermediates and Reagents: The synthesis pathway typically involves several key chemical transformations. While proprietary synthesis routes can vary between manufacturers, common steps and materials include:

  • Amination Reagents: Chemicals used to introduce the amino group onto the pyridine ring. Examples include ammonia or other amine sources under specific reaction conditions.
  • Halogenated Pyridines: Intermediate compounds where a halogen atom (e.g., chlorine or bromine) is substituted onto the pyridine ring, facilitating subsequent amination.
  • Catalysts: Various catalysts are employed to facilitate specific reaction steps, such as palladium catalysts for coupling reactions or acid/base catalysts for functional group transformations.
  • Solvents: A range of organic solvents are used throughout the synthesis process, including but not limited to, alcohols, ethers, and chlorinated solvents. The sourcing and management of these solvents are critical operational considerations.
  • Purification Agents: Chemicals used in the crystallization and purification of the final API, such as anti-solvents and adsorbents.

The supply chain for these intermediates can be complex, often involving specialized chemical manufacturers. Geographic concentration of suppliers for specific intermediates can pose a risk. For instance, if a critical catalyst or a unique halogenated pyridine intermediate is sourced from a single region, geopolitical events or natural disasters in that region could disrupt production.

Regulatory Landscape and Compliance

The production of dalfampridine API and drug product is subject to rigorous regulatory oversight by health authorities worldwide. Compliance with current Good Manufacturing Practices (cGMP) is non-negotiable.

• Key Regulatory Bodies:

  • U.S. Food and Drug Administration (FDA): Oversees drug manufacturing and quality in the United States. FDA inspections of API and finished product sites are critical for market approval and continuous supply.
  • European Medicines Agency (EMA): The regulatory body for the European Union. EMA approval requires adherence to EU GMP standards.
  • Pharmaceuticals and Medical Devices Agency (PMDA) (Japan): The Japanese regulatory authority.
  • Other National Regulatory Authorities: Each country where dalfampridine is marketed has its own regulatory requirements.

• cGMP Requirements: Manufacturers must demonstrate robust quality management systems, including:

  • Process Validation: Ensuring that manufacturing processes consistently produce API meeting predetermined specifications.
  • Analytical Method Validation: Validating the accuracy, precision, and reliability of tests used to assess API quality.
  • Impurity Profiling: Identifying and controlling all process-related impurities and degradation products within acceptable limits.
  • Stability Testing: Assessing the shelf-life and storage conditions of the API.
  • Traceability: Maintaining detailed records for every batch, from raw materials to finished API.

Any regulatory action, such as a warning letter or import alert issued by the FDA or EMA against an API supplier, can have immediate and severe consequences for drug manufacturers relying on that source. This can lead to product shortages, forced recalls, and significant financial penalties.

Geographic Distribution of Dalfampridine Supply

The manufacturing of dalfampridine API and its key intermediates is spread across several continents, reflecting globalized pharmaceutical supply chains.

• North America: While finished drug product manufacturing may occur here, primary API synthesis is less concentrated compared to other regions, often relying on imported APIs.
• Europe: Several API manufacturers and CDMOs, particularly in countries like Germany, Ireland, and Switzerland, are involved in producing complex pharmaceutical intermediates and APIs, including dalfampridine.
• Asia: This region, especially India and China, is a major hub for API manufacturing due to cost advantages and established chemical industries. Many generic API suppliers for dalfampridine operate from these countries.

The geographic distribution has implications for supply chain resilience. Over-reliance on any single region for critical components can create vulnerabilities to geopolitical instability, trade disputes, or localized environmental events. Diversification of manufacturing sites is a strategy to mitigate these risks.

Competitive Landscape and Generic Entry

The patent landscape for dalfampridine influences the market dynamics and the number of suppliers. As patents expire, generic manufacturers can enter the market, increasing competition and potentially lowering prices.

• Original Innovator: Biogen (formerly Acorda Therapeutics) held the initial patents for dalfampridine (Ampyra).
• Generic Entry: Following patent expiries or successful patent challenges, multiple generic versions of dalfampridine have entered the market in various regions. This typically leads to:
  • Increased API Demand: More manufacturers require API, potentially leading to increased production from existing and new API suppliers.
  • Price Pressure: Generic competition drives down the price of both the finished drug and, consequently, the API.
  • Supplier Diversification: To secure cost-effective supply, generic drug companies often seek multiple API suppliers, including those in emerging markets.

The competitive entry of generics signifies a maturing market, where cost efficiency and reliable supply become paramount. The ability of API suppliers to offer competitive pricing while maintaining cGMP compliance is a key differentiator.

Potential Supply Chain Risks and Mitigation Strategies

Several factors can pose risks to the dalfampridine supply chain. Proactive risk management is essential for pharmaceutical companies.

• Key Risks:

  • Single-Source Dependence: Reliance on a sole supplier for a critical intermediate or the API itself.
  • Quality Failures: API batches failing to meet cGMP standards, leading to rejections and production delays.
  • Regulatory Non-Compliance: API manufacturing sites being delisted or facing import restrictions due to regulatory violations.
  • Geopolitical Instability: Trade wars, political unrest, or natural disasters impacting key manufacturing regions.
  • Raw Material Shortages: Disruption in the supply of basic chemicals or reagents necessary for synthesis.
  • Logistical Disruptions: Issues with transportation, customs, or port operations affecting the movement of materials and finished API.

• Mitigation Strategies:

  • Dual/Multi-Sourcing: Qualifying and maintaining relationships with at least two independent suppliers for critical raw materials, intermediates, and API.
  • Supplier Audits and Qualification: Conducting regular, thorough audits of all suppliers to ensure ongoing compliance with quality and regulatory standards.
  • Inventory Management: Maintaining strategic buffer stocks of critical materials and API to cushion against short-term supply disruptions.
  • Geographic Diversification: Sourcing materials and manufacturing from different geographical regions to reduce single-point failure risks.
  • Contingency Planning: Developing robust business continuity plans that outline steps to take in the event of identified supply chain disruptions.
  • Strong Contractual Agreements: Establishing clear terms with suppliers regarding quality, delivery schedules, and intellectual property protection.
  • Early Engagement with Regulatory Authorities: Maintaining open communication with regulatory bodies regarding any potential supply chain challenges.

Conclusion

The dalfampridine supply chain involves specialized API manufacturers and a network of chemical intermediate suppliers. Key players include Catalent and Hovione, alongside significant generic API production from India and China. The synthesis relies on fundamental chemicals like pyridine and a range of organic reagents. Regulatory compliance, particularly cGMP, is a critical determinant of supplier viability. While a diversified geographic presence exists, risks such as single-source dependence and quality failures necessitate robust mitigation strategies including dual-sourcing and comprehensive supplier oversight. The entry of generic competitors underscores the importance of cost-effective and reliable API sourcing.

Key Takeaways

• Dalfampridine API is manufactured by specialized CDMOs like Catalent and Hovione, as well as numerous generic API producers, primarily in Asia.
• The synthesis originates from pyridine and involves various chemical intermediates and reagents.
• Stringent cGMP compliance is mandatory for all API and drug product manufacturers.
• Supply chain risks include quality failures, regulatory non-compliance, and geopolitical instability.
• Mitigation strategies focus on dual-sourcing, geographic diversification, and rigorous supplier qualification.
• Generic entry has increased API demand and driven cost-efficiency requirements for suppliers.

Frequently Asked Questions

1. What is the primary chemical structure of dalfampridine that influences its API manufacturing? The primary chemical structure is 4-aminopyridine.
2. Which regions are most significant for dalfampridine API production? Asia, particularly India and China, is a major hub for generic API production, while Europe and North America have specialized CDMO capabilities.
3. What is the role of contract development and manufacturing organizations (CDMOs) in the dalfampridine supply chain? CDMOs like Catalent and Hovione are critical for the development and large-scale manufacturing of dalfampridine API, adhering to pharmaceutical quality standards.
4. How does generic competition impact dalfampridine API suppliers? Generic competition typically increases demand for API and exerts downward pressure on pricing, requiring suppliers to focus on cost-effectiveness and reliable, high-volume production.
5. What are the most common regulatory challenges faced by dalfampridine API manufacturers? Manufacturers must consistently adhere to cGMP, which includes rigorous process validation, impurity control, and robust quality management systems to avoid regulatory actions such as warning letters or import alerts.

Citations

[1] Biogen. (n.d.). Ampyra® (dalfampridine) prescribing information. Retrieved from [Manufacturer's Website/Regulatory Database] [2] European Medicines Agency. (n.d.). Fampyra (dalfampridine). Retrieved from [EMA Website] [3] U.S. Food and Drug Administration. (n.d.). Drug Shortages. Retrieved from [FDA Website] [4] Hovione. (n.d.). Active Pharmaceutical Ingredients Portfolio. Retrieved from [Hovione Website] [5] Catalent Pharma Solutions. (n.d.). API Manufacturing Services. Retrieved from [Catalent Website]